Business
Completion of Nominated Adviser due diligence
Completion of Nominated Adviser due diligence.
About this update from Ondine Biomedical, Inc.
[{"type":"text","content":"\n \n \n 26 July 2022 \n \n \n \n Ondine Biomedical Inc.\n \n \n \n (\"Ondine Biomedical\", \"Ondine\" or the \"Company\")\n \n \n \n Completion of Nominated Adviser due diligence\n \n \n Ondine Biomedical Inc. (AIM: OBI) announces that Strand Hanson Limited, appointed as the Company's Nominated Adviser on 27 April 2022, has confirmed completion of its due diligence.\n \n Pursuant to Schedule 2(g)(ii) of the AIM Rules for Companies, the following disclosures are required:\n \n \n \n \n \n \n Director\n \n \n \n \n Current directorships\n \n \n \n \n \n Carolyn Cross\n \n \n 12673011 Canada Inc.\n \n \n \n \n Nicolas Loebel\n \n \n Advanced Photodynamic Technologies Inc.\n Axcess Medical Inc.\n Ondine Research Laboratories Ltd\n \n \n \n \n \n \n \n \n For more information, please visit: www.ondinebio.com or contact: \n \n \n \n \n \n \n \n \n Ondine Biomedical Inc. \n \n \n \n Carolyn Cross, CEO +001 (1) 604 669 0555\n \n \n \n \n \n \n Strand Hanson Limited (Nominated and Financial Adviser)\n \n \n \n Richard Johnson, James Harris, James Dance +44 (0) 20 7409 3494\n \n \n \n \n \n \n Arden Partners plc (Broker)\n \n \n \n Ruari McGirr +44 (0) 20 7614 5900\n \n \n \n \n \n \n \n \n Vane Percy & Roberts (Media Contact)\n \n \n \n Simon Vane Percy, Amanda Bernard \n +44 (0) 77 1000 5910\n \n \n ","length":4557,"tagName":"div"}]